



head

office

in

Special Power of Attorney

Entity(company)

for representation in the Ordinary General Meeting of Shareholders of Antibiotice SA on $\underline{26/27.08.2025}$

			(city),		county,			_street no	, re	egiste	ered
at	the	Trade	Register	Office	under		,	fiscal	code	:	no.
				, in capa	city of hol	der of	(no.)	s	hares ar	noun	ting
to _		% of t	total shares issi	ued by Antil	oiotice SA	and red	corded i	n the Shar	eholder	Regi	ster
of	the	Central	Depository	Buchar	est, le	gally	repre	esented	by	Mr./	Ms.
				iden	tified by N	lational	l Identif	ication Nu	mber		
ID s	eries	_ no	which gra	nt me	vc	otes (% of total	voting ı	rights	i) in
the	General	Meeting o	of the Shareho	lders held o	on <u>26/27.(</u>	08.202	<u>5</u> , here	inafter re	ferred t	o as	the
prir	ncipal,	and Mr	./Ms					,	resid	ent	of
		,	street		no, ide	entified	by Nati	onal Ident	ification	Num	ıber
		ID	series	no	or	in	their	absence,	Mr.	/	Ms.
				resident o	f			_, street			
no.	, iden	tified by N	lational Identifi	cation Num	oer	ID	series _	_ no	, a	ppoin	ited
as a	ttorney-	in-fact.									
I, th	ne princi	pal, hereb	y invest the at	torney-in-fa	act with fu	ıll powe	ers in ex	certing the	voting	right	s in
the	name a	nd on bel	nalf of the pri	ncipal (rela	tive to th	ne shar	res own	ed and re	egistered	d in	the
Sha	reholders	Register l	oy 14.08.2025	as the refe	ence date	e), in th	ne OGMS	held at A	ntibiotic	e HQ	Į on
<u> 26.</u>	08.2025	, at 10:00	am, and, respe	ctively in th	ne second	meetin	ıg organ	ized on <u>27</u>	7.08.202	25 10):00
am,	as per t	he legal pr	ovisions of art.	118 Law 31	/1990 repu	ublished	d.				

No	Agenda for the	Option			
	Ordinary General Meeting of Shareholders	for	against	abstention	
0	1	2	3	4	
1.	Approval of the project entitled "Research and Development Center Inova a+ and critical medicines production" which will				

			1
	be submitted for funding under the Health Program, Project Call "Support for STEP-compatible projects submitted within the project ideas call in the field of health / with applicability in the health sector, organized by the Health Program Managing Authority (AMPS)", Priority 9, "Contribution to the STEP Platform: biotechnologies and digital technologies, including associated services in the health sector" and the related expenses in value of 376,877,912.87 lei, VAT-free. Antibiotice S.A. undertakes to ensure that it has the financial capacity to provide its own contribution to both the eligible and non-eligible project expenditures, under the conditions of subsequent reimbursement/settlement of the expenses. Antibiotice S.A. undertakes, for a 5-year period from the date of completion of the investment, in accordance with the state aid scheme and the provisions of Article 65 of Regulation (EU) No. 2021/1060, to maintain the investment made by covering the related operating and maintenance costs, as well as the necessary associated services, in order to ensure its financial sustainability.		
2.	Approval of the technical and economic indicators of the project entitled "Research and Development Center Inova a+ and critical medicines production", which will be submitted for financing under the Health Program, Project Call "Support for STEP-compatible projects submitted within the project ideas call in the field of health / with applicability in the health sector, conducted by Health Program Managing Authority", Priority 9, Contribution to the STEP Platform: biotechnologies and digital technologies, including associated services in the health sector".		
3.	Authorization of the Management Board to issue resolutions approving, based on supporting documentation, the exact amount of expenses related to the project "Research and Development Center Inova a+ and critical medicines production" and its technical-economic indicators which will be submitted for funding under the Health Program, Project Call "Support for STEP-compatible projects submitted within the project ideas call in the field of health / with applicability in the health sector, organized by the Health Program Managing Authority (AMPS)", Priority 9, Contribution to the STEP Platform: biotechnologies and digital technologies, including associated services in the health sector, provided they are kept within the maximum value of 376,877,912.87 lei, VAT-free.		

I hereby authorize my above mentioned attorney-in-fact to vote according to the way he/she was empowered.

I give him/her discretionary power on the issues that haven't been identified and included on the agenda by the date of issuing the hereby Power of Attorney.

Yes □	No	
-------	----	--

I hereby attach a copy of the valid registration certificate.

Drafted today,, in three original copies with similar legal power: one for the
principal, one for the attorney-in-fact and the third to be recorded at Antibiotice SA Registrar's
Office by 24.08.2025, 10:00 am.
Contact phone no
PRINCIPAL (Securities holder),
(Name of the entity acting as principal, in capitals)
(Last name and first name of the attorney-in-fact, in capitals)
(Seal and signature of the attorney-in-fact)

Note:

The Power of Attorney will be modified and completed accordingly if, in accordance with the legislation in force, one or more shareholders representing, individually or together, at least 5% of the share capital will introduce new items on the agenda of the general meeting. In the event of updating the Power of Attorney form, please check the requirements in the GM Convening Notice starting with the 16th day after the publication of the Convening Notice.

After filling in and signing the special Power-of-Attorney, an original copy shall be submitted/sent to Antibiotice headquarters, in a sealed envelope, mentioning the confidential nature of the content, so that it is recorded at the Antibiotice SA Registrar's Office by 24.08.2025, 10:00 am at the latest.